ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Quinolones >Nalidixic acid

Nalidixic acid

Nalidixic acid Suppliers list
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Nalidixic acid
Purity:99.00% Package:100g,500g,1KG,10KG,100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: CAS:389-08-2
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Products Intro: Product Name:Nalidixic acid
Company Name: career henan chemical co
Tel: +86-371-86658258
Products Intro: Product Name:Nalidixic acid
Purity:99% Package:1kg;2USD
Company Name: Chemwill Asia Co.,Ltd.
Tel: 86-21-51086038
Products Intro: CAS:389-08-2
Purity:99% Package:5KG;1KG;25KG PRICE quotation Remarks:Factory stock, quality assurance, price concessions

Lastest Price from Nalidixic acid manufacturers

  • Nalidixic acid
  • US $2.00 / kg
  • 2019-07-06
  • CAS:389-08-2
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
Nalidixic acid Basic information
Product Name:Nalidixic acid
Product Categories:Heterocyclic Compounds;Antibiotics for Research and Experimental Use;Biochemistry;Quinolones (Antibiotics for Research and Experimental Use);Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;NegGram, Nevigramon, Nalidixin, Uronidix;antibiotic
Mol File:389-08-2.mol
Nalidixic acid Structure
Nalidixic acid Chemical Properties
Melting point 227-229 °C(lit.)
Boiling point 374.4°C (rough estimate)
density 1.2243 (rough estimate)
refractive index 1.6660 (estimate)
storage temp. 0-6°C
solubility chloroform: 20 mg/mL, clear
pkapKa 6.11± 0.02(Approximate)
form Powder
color White to light yellow
Water Solubility 0.1 G/L (23 ºC)
Merck 14,6359
BRN 750515
Stability:Stable. Incompatible with strong oxidizing agents.
CAS DataBase Reference389-08-2(CAS DataBase Reference)
EPA Substance Registry System1,8-Naphthyridine- 3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl- 4-oxo-(389-08-2)
Safety Information
Hazard Codes Xn
Risk Statements 63-42/43-40-20/21/22-22
Safety Statements 22-36/37-45-24-36
WGK Germany 2
RTECS QN2885000
HS Code 29339190
Hazardous Substances Data389-08-2(Hazardous Substances Data)
ToxicityLD50 in mice (mg/kg): 3300 orally; 500 s.c.; 176 i.v. (Lesher, 1962)
MSDS Information
Nalidixic acid Usage And Synthesis
Chemical PropertiesCrystalline Powder
UsesQuinolone antibacterial.
UsesNalidixic acid(NegGram) is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase. Evidence exists that the active metabolite, hydroxynalidixic acid, binds stron
UsesFor the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species.
DefinitionChEBI: A monocarboxylic acid comprising 1,8-naphthyridin-4-one substituted by carboxylic acid, ethyl and methyl groups at positions 3, 1, and 7, respectively.
Brand nameNeggram(Sanofi Aventis).
Antimicrobial activityIt displays good activity in vitro against a wide range of Enterobacteriaceae.
General DescriptionCream-colored powder.
Air & Water ReactionsInsoluble in water.
Health HazardSYMPTOMS: Ingestion of Nalidixic acid may cause nausea, vomiting, abdominal pain, allergic reactions and possible liver damage.
Fire HazardFlash point data for Nalidixic acid are not available, but Nalidixic acid is probably combustible.
Pharmaceutical ApplicationsA 1,8 naphthyridone derivative available for oral administration.
PharmacokineticsOral absorption: >90%
Cmax 1 g oral: c. 25 mg/L
Plasma half-life:c.1.5h
Volume of distribution :0.4 L/kg
Plasma protein binding: 93%
The plasma concentrations achieved after oral administration vary widely. In infants with acute shigellosis, absorption is much impaired by diarrhea. Administration with an alkaline compound leads to higher plasma concentrations, partly as the result of enhanced solubility (nalidixic acid is much more soluble at higher pH) and absorption and partly because of reduced tubular reabsorption.
It is rapidly metabolized, principally to the hydroxy acid, which is bacteriologically active, and glucuronide conjugates, which are not. The entire administered dose appears in the urine over a 24 h period. Elimination is reduced by probenecid. In the presence of renal impairment there is little accumulation of the active compound because it continues to be metabolized. However, elimination of metabolites is progressively delayed as renal function declines. About 4% of a dose appears in the feces.
Clinical Use1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid (NegGram) occurs as a pale buff crystalline powder that is sparingly soluble in water and ether but solublein most polar organic solvents.Nalidixic acid is useful in the treatment of urinary tractinfections in which Gram-negative bacteria predominate.The activity against indole-positive Proteus spp. is particularlynoteworthy, and nalidixic acid and its congeners representimportant alternatives for the treatment of urinary tractinfections caused by strains of these bacteria resistant toother agents. Nalidixic acid is rapidly absorbed, extensivelymetabolized, and rapidly excreted after oral administration.The 7-hydroxymethyl metabolite is significantly more activethan the parent compound. Further metabolism of theactive metabolite to inactive glucuronide and 7-carboxylicacid metabolites also occurs. Nalidixic acid possesses at1/2elim of 6 to 7 hours. It is eliminated, in part, unchanged inthe urine and 80% as metabolites.
Side effectsAdverse reactions are generally those common to all quinolones: gastrointestinal tract and CNS disturbances and skin rashes, including eruptions related to photosensitivity. About half of the reported CNS reactions involve visual disturbances, hallucinations or disordered sensory perception. Severe excitatory states, including acute psychoses and convulsions, are usually observed in patients receiving high dosages. The drug should be avoided in patients with psychiatric disorders or epilepsy.
Acute intracranial hypertension has been observed in children, some of whom have also manifested cranial nerve palsies. Hemorrhage has occurred in patients who were also receiving warfarin, presumably due to displacement of the anticoagulant from its protein binding sites by the nalidixic acid. Hemolytic anemia has been described several times in infants with or without glucose-6-phosphate dehydrogenase deficiency; in adults, death has occurred from autoimmune hemolytic anemia. Arthralgia and severe metabolic acidosis have rarely been reported.
Safety ProfilePoison by intravenous and intraperitoneal routes. Moderately toxic by ingestion and subcutaneous routes. An experimental teratogen. Human systemic effects: convulsions, hyperglycemia, sweating, and blood changes in children. Experimental reproductive effects.Questionable carcinogen with experimental carcinogenic and tumorigenic data. Human mutation data reported. Used as an antibacterial agent and urinary tract antiseptic. When heated to decomposition it emits toxic fumes of NOx.
Purification MethodsNalidixic acid crystallises from H2O or EtOH as a pale buff powder. It is soluble at 23o in CHCl3 (3.5%), toluene (0.16%), MeOH (0.13%), EtOH (0.09%), H2O (0.01%) and Et2O (0.01%). It inhibits nucleic acid and protein synthesis in yeast. [Lesher et al. J Med & Pharm Chem 5 1063 1962.]
Tag:Nalidixic acid(389-08-2) Related Product Information
NALIDIXIC ACID SODIUM SALT,nalidixic acid sodium gamma-irradiated*molecular,nalidixic acid sodium,NALIDIXIC ACID SODIUM GAMMA-IRRADIATED*M OLECULAR BI,NALIDIXIC ACID SODIUM SALT MOLECULAR BIOLOGY REAGENT AMFONELIC ACID Methyl Acetonitrile Methanol CARBOXYLIC ACID 2-Butanone oxime phosphoric acid Methylparaben Methyl acrylate 2-Methylnaphthalene Basic Violet 1 METHYL ETHYLCELLULOSE Methyl 2-hydroxyethyl cellulose Kresoxim-methyl Glycine Ethyl 2-(Chlorosulfonyl)acetate 2,6-DIMETHYLNAPHTHALENE